Acitretin
- PMID: 30137855
- Bookshelf ID: NBK519571
Acitretin
Excerpt
Acitretin, a member of the retinoid drug class, is the sole FDA-approved systemic retinoid for treating psoriasis, exhibiting efficacy as a standalone therapeutic agent. Retinoids encompass natural and synthetic compounds, similar to vitamin A, and influence various physiological processes. Vitamin A, a vital regulator of the immune system, contributes to cellular growth, differentiation, and proliferation and plays a crucial role in embryonic development. Noteworthy effects of retinoids extend to immunologic anti-inflammatory actions, apoptosis induction, and inhibition of tumor promotion. Beyond its sanctioned use in psoriasis, acitretin finds application in dermatology for off-label purposes. This activity examines the indications, contraindications, and potential adverse events linked to acitretin, empowering interprofessional healthcare team members to manage patients collaboratively and ensure optimal medication utilization in clinical settings.
Copyright © 2025, StatPearls Publishing LLC.
Conflict of interest statement
Sections
References
-
- Ighani A, Partridge ACR, Shear NH, Lynde C, Gulliver WP, Sibbald C, Fleming P. Comparison of Management Guidelines for Moderate-to-Severe Plaque Psoriasis: A Review of Phototherapy, Systemic Therapies, and Biologic Agents. J Cutan Med Surg. 2019 Mar/Apr;23(2):204-221. - PubMed
-
- Skillen LA, Corry A. Combination therapy of sirolimus and acitretin in solid organ transplant recipients: a new cutaneous adverse event. Clin Exp Dermatol. 2019 Jan;44(1):62-63. - PubMed
-
- Kaushik SB, Lebwohl MG. Review of safety and efficacy of approved systemic psoriasis therapies. Int J Dermatol. 2019 Jun;58(6):649-658. - PubMed
Publication types
LinkOut - more resources
Full Text Sources